nicotinic acid

Cílem naší studie bylo: (1) sledovat změny plazmatických koncentrací NEFA v průběhu 24 hodin po třetí dávce jednorázového podání niacinu v množství 500 mg/den (Niaspan ®) a stanovit jejich vztah k plazmatickým koncentracím kyseliny nikotinové (NA) a jejích metabolitů: nikotinamidu (NAM), 1-methyl-nikotinamidu (MNA), N-methyl-2-pyridon-5- karboxamidu (2-Pyr), N-methyl-4-pyridon-5-karboxamidu (4-Pyr) a kyseliny nikotinurové (NUA); (2) zjistit, zda se koncentracemi niacinu (resp. jeho metabolitů) a NEFA lišily osoby, u kterých došlo k rozvoji kožních změn (flush), od osob bez nežádoucích kožních projevů.

Elevated plasma concentrations of non-esterified fatty acids (NEFA) have been associated with lipotoxicity, ectopic fat deposition in organs and tissues (liver, skeletal muscle, pancreas), chronic heart failure, suppressed growth hormone secretion, and ventricular arrhythmias. A long-term clinical experience indicates that niacin (nicotinic acid) produces beneficial effects on dyslipidemias and slows down progression of atherosclerotic cardiovascular disease. One of the mechanisms of the hypolipidemic effect of niacin is reduction of NEFA release from adipose tissue into free circulation, which is mediated by activated HCA2 receptors in adipocytes. To study plasma concentrations of niacin and its metabolites in relation to plasma NEFA changes. Plasma concentrations of niacin, its metabolites, and NEFA were assessed in 12 healthy subjects (5 M/7 F) of middle age (44.2 ± 12.5 years), after a single oral dose of 500 mg of niacin (Niaspan®), applied on three successive days. After the third dose, niacin and its metabolites were determined by a HPLC- MS method, NEFA by an enzymatic-colorimetric method.